U.S. Markets closed

Curis mentioned positively following Roche data at Cowen

Cowen said news Roche has initiated Phase Ib/II trial evaluating Erivedge in patients with relapsed/refractory acute myelogenous leukemia and relapsed/refractory, high-risk myelodysplastic syndrome is a incremental positive for Curis as it indicates Roche's commitment to developingadditional indications.